

## AMENDMENTS TO THE SPECIFICATION

1. Please amend the Paragraph [0001] on page 1 as follows:


The present application claims the benefit under 35 U.S.C. § 371 of International Application No.: PCT/US03/00390 (published PCT application No. WO 03/59898), filed January 8, 2003, which claims priority to U.S. Patent Application Serial Number 60/346,711, filed January 8, 2002, and U.S. Patent Application Number 60/373,011, filed April 16, 2002, the entire contents of ~~which~~ each of the above applications are incorporated herein by reference.

2. In addition, the Examiner is directed to the International Preliminary Examination Report (IPER) issued February 5, 2004 in which it is reported that Applicant's amendments to the claims and specification filed on November 19, 2003 under PCT Article 34 have been entered. Specifically, paragraph [0008] has been amended to replace "A, J, C, D or G" with "A, J, E, D or G."

3. Please further amend paragraph [0008] as follows:

*1) General Description of Compounds of the Invention*

The compounds of the invention include compounds of the general formula (I) as further defined below:



and pharmaceutically acceptable derivatives thereof;

wherein each occurrence of ~~A, J, E, D or G~~ A, J, E, D and G is independently absent, CR<sub>A</sub>, CR<sub>A</sub>R<sub>B</sub>, C=O, O, S, NR<sub>A</sub>, or N, wherein each occurrence of R<sub>A</sub> and R<sub>B</sub> is independently

hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety;

A and J, J and D, D and E, and D and G are each independently linked by a single or double bond as valency permits;

w, x, y and z are each independently 0, 1, 2, 3, 4, 5 or 6, but the sum of x, y and z is 0-6;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are each independently hydrogen, halogen, -CN, -OR<sub>C</sub>, -SR<sub>C</sub>, -NR<sub>C</sub>R<sub>D</sub>, -(C=O)R<sub>C</sub> or an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, wherein each occurrence of R<sub>C</sub> and R<sub>D</sub> is independently hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, or R<sub>C</sub> and R<sub>D</sub>, taken together, form a heteroalicyclic or heteroaryl moiety; or wherein any two adjacent groups R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub>, taken together, form an alicyclic or heteroalicyclic moiety, or an aryl or heteroaryl moiety;

R<sub>5</sub> and R<sub>6</sub> are each independently an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety; and

Q is an O-containing heteroaliphatic or heteroalicyclic moiety.